DB:MGNK

Stock Analysis Report

Executive Summary

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases.

Rewards

Trading at 99.8% below its fair value

Earnings are forecast to grow 192.86% per year

Risk Analysis

Makes less than USD$1m in revenue (€386K)

Does not have a meaningful market cap (€2M)

Has less than 1 year of cash runway

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

High growth potential and slightly overvalued.

Share Price & News

How has Mologen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGNK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.6%

MGNK

6.2%

DE Biotechs

1.0%

DE Market


1 Year Return

-94.5%

MGNK

10.1%

DE Biotechs

14.2%

DE Market

Return vs Industry: MGNK underperformed the German Biotechs industry which returned 10.1% over the past year.

Return vs Market: MGNK underperformed the German Market which returned 14.2% over the past year.


Shareholder returns

MGNKIndustryMarket
7 Day-20.6%6.2%1.0%
30 Day-85.1%17.2%0.04%
90 Day-83.1%9.1%6.0%
1 Year-94.3%-94.5%10.3%10.1%17.8%14.2%
3 Year-98.0%-98.2%80.4%78.3%19.2%8.7%
5 Year-99.4%-99.5%15.6%13.2%36.0%17.5%

Price Volatility Vs. Market

How volatile is Mologen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mologen undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MGNK (€0.15) is trading below our estimate of fair value (€97.69)

Significantly Below Fair Value: MGNK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGNK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MGNK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGNK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGNK has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is Mologen forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

192.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: MGNK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MGNK's is expected to become profitable in the next 3 years.

Revenue vs Market: MGNK's revenue (259.1% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: MGNK's revenue (259.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MGNK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mologen performed over the past 5 years?

5.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGNK is currently unprofitable.

Growing Profit Margin: MGNK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGNK is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.

Accelerating Growth: Unable to compare MGNK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGNK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: MGNK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Mologen's financial position?


Financial Position Analysis

Short Term Liabilities: MGNK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: MGNK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: MGNK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: MGNK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: MGNK has a low level of unsold assets or inventory.

Debt Coverage by Assets: MGNK has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGNK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MGNK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Mologen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MGNK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MGNK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGNK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGNK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGNK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Mologen's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average board tenure


CEO

Stefan Manth (63yo)

0.6yrs

Tenure

€59,000

Compensation

Dr. Stefan M. Manth, M.D., Ph.D., MBA, has been Chief Executive Officer of Genelux Europe and President of Genelux Europe at Genelux Corporation since July 1, 2013. Dr. Manth served as Partner and Change L ...


Board Age and Tenure

1.5yrs

Average Tenure

Experienced Board: MGNK's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.8%.


Management Team

  • Burghardt Wittig

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: €576.00k
  • Stefan Manth (63yo)

    CEO & Member of the Executive Board

    • Tenure: 0.6yrs
    • Compensation: €59.00k
  • Matthias Baumann (61yo)

    Chief Medical Officer & Member of Executive Board

    • Tenure: 2.6yrs
    • Compensation: €346.00k
  • Claudia Nickolaus

    Head of Investor Relations & Corporate Communications

    • Tenure: 0yrs

Board Members

  • Burghardt Wittig

    Co-Founder & Chairman of Scientific Advisory Board

    • Tenure: 0yrs
    • Compensation: €576.00k
  • Ulrich Granzer (58yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Oliver Krautscheid (51yo)

    Chairman of the Supervisory Board

    • Tenure: 5.3yrs
    • Compensation: €78.00k
  • Dirk Arnold

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Viktor Grünwald

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Schultz

    Member of the Supervisory Board

    • Tenure: 1.5yrs
    • Compensation: €23.00k
  • Friedrike Zahm

    Member of the Supervisory Board

    • Tenure: 0.9yrs

Company Information

Mologen AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mologen AG
  • Ticker: MGNK
  • Exchange: DB
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.729m
  • Shares outstanding: 12.44m
  • Website: https://www.mologen.com

Number of Employees


Location

  • Mologen AG
  • Fabeckstrasse 30
  • Berlin
  • Berlin
  • 14195
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGNKDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1999
0IYNLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 1999
MGNKXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURJun 1999
MGNKDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1999
MGNDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1999

Biography

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/13 21:07
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.